Population Pharmacokinetics and Exposure-Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1.

导出 OA

翻译打印收藏纠错

第一作者： Xin,Miao

第一单位： Janssen Research & Development, Spring House, PA, USA. xmiao0831@gmail.com.

作者： Xin,Miao ^[1] ; Liviawati S,Wu ^[2] ; Shun Xin Wang,Lin ^[3] ; Yan,Xu ^[3] ; Yang,Chen ^[3] ; Yuki,Iwaki ^[4] ; Rachel,Kobos ^[5] ; Tara,Stephenson ^[3] ; Kristy,Kemmerer ^[3] ; Clarissa M,Uhlar ^[3] ; Arnob,Banerjee ^[3] ; Jenna D,Goldberg ^[5] ; Danielle,Trancucci ^[5] ; Amit,Apte ^[5] ; Raluca,Verona ^[3] ; Lixia,Pei ^[5] ; Rachit,Desai ^[5] ; Kathleen,Hickey ^[3] ; Yaming,Su ^[5] ; Daniele,Ouellet ^[3] ; Mahesh N,Samtani ^[3] ; Yue,Guo ^[3] ; Alfred L,Garfall ^[6] ; Amrita,Krishnan ^[7] ; Saad Z,Usmani ^[8] ; Honghui,Zhou ^[3] ; Suzette,Girgis ^[3]

作者单位： Janssen Research & Development, Spring House, PA, USA. xmiao0831@gmail.com. ^[1] Janssen Research & Development, South San Francisco, CA, USA. ^[2] Janssen Research & Development, Spring House, PA, USA. ^[3] Janssen Pharmaceutical KK, Tokyo, Japan. ^[4] Janssen Research & Development, Raritan, NJ, USA. ^[5] Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. ^[6] City of Hope Comprehensive Cancer Center, Duarte, CA, USA. ^[7] Memorial Sloan Kettering Cancer Center, New York, NY, USA. ^[8]

主题词人类(Humans);多发性骨髓瘤(Multiple Myeloma);抗肿瘤药(Antineoplastic Agents);中性粒细胞减少(Neutropenia);体重(Body Weight)

DOI 10.1007/s11523-023-00989-z

PMID 37713090

发布时间 2023-11-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交